Here is Why Ocular Therapeutix (OCUL) is Highly Favored by Hedge Funds

On March 3, Tazeen Ahmad from Bank of America Securities accrued the terms people connected Ocular Therapeutix Inc. (NASDAQ:OCUL) from $24 to $27 portion maintaining a Buy standing connected the stock. This results successful a revised upside imaginable of much than 257% for investors.

wavebreakmedia/Shutterstock.com

According to Ahmad, a thorough introspection of the Phase 3 SOL1 proceedings results offers compelling grounds successful favour of the support and hazard simplification that the diabetic retinopathy programme offers done clarifying important questions.

On March 3, Clear Street raised its terms people connected Ocular Therapeutix Inc. (NASDAQ:OCUL) from $21 to $28. The steadfast maintained its Buy standing connected the shares. Clear Street cited affirmative information from the SOL-1 trial, noting the results enactment Axpaxli’s imaginable to present durable power successful bedewed AMD.

Clear Street added that the therapy could code a cardinal unmet request astir dosing intervals, with beardown efficacy and a favorable information illustration supporting a much constructive outlook.

Ocular Therapeutix Inc. (NASDAQ:OCUL) focuses connected processing and commercializing therapeutics for antithetic oculus conditions, including retinal diseases, utilizing its bioresorbable hydrogel-based formulation technology. Its portfolio includes DEXTENZA, AXPAXLI successful signifier 3 of objective trial, and OTX-TIC successful signifier 2 of objective trial.

While we admit the imaginable of OCUL arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.